Kaiser Permanente Mid-Atlantic HCV repository (KPMAS)
KPMAS is an integrated healthcare system that serves more than 500,000 individuals in in the Northeast and includes publicly and privately insured individuals. The KPMAS HCV repository includes information on demographics, clinical encounters, laboratory test results, and pharmacy data for enrollees.
Rodriguez CV, Rubenstein KB, Linas B, Hu H, Horberg M. Increasing hepatitis C screening in a large integrated health system: science and policy in concert. Am J Manag Care. 2018;24(5):e134-e140. PMID: 29851444
Boston Alcohol Research Collaboration on HIV/AIDS (Boston ARCH) Cohort
The Boston ARCH is a cohort of HIV-infected patients with risky alcohol or drug use. The cohort uses a traditional observational design, with every 6-month study visits conducted outside of the clinical setting. Study assessments capture detailed characterization of alcohol and drug use, including validated measures of quantity and frequency of use of a variety of substances, as well as their impact on quality of life, criminal activity, and general health status.
Health Insurance Claims
Marketscan - Truven Health Analytics
MarketScan® databases capture health insurance claims-based data from more than 200 million unique patients dating back to 2006. The Commercial claims database captures complete payment information, including patient out-of-pocket co-payments and deductibles as well as clinical diagnoses and procedures associated with each claim. Specialty pharmacy and mail order pharmacy data are included.
Barocas JA, Wang J, White LF, Tasillo A, Salomon JA, Freedberg KA, Linas BP. Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Affairs. 2017 Dec;36(12):2142-2150. PMID: 29200354
Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90-96. PMID: 28733097
Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug and alcohol dependence. 2019;200:34-9. PMID: 31082666
“Medications for opioid use disorder saves lives.” That’s the title and conclusion of a recent report by the National Academies of Sciences, Engineering and Medicine, based on a review of the scientific evidence. In a new study in Drug and Alcohol Dependence, CHERISH investigators Jake Morgan, Bruce Schackman and Benjamin Linas add to this evidence base by examining […]
Hepatitis C virus (HCV) is a communicable disease that could lead to liver cirrhosis and hepatocellular carcinoma affecting baby boomers and all people who inject drugs (PWID) in particular. There are over 19,000 HCV-related deaths in the United States annually. HCV can be cured using direct-acting antivirals that can also reverse HCV-related liver injury. In […]
In response to the growing opioid epidemic in the United States there is an increased focus on expanding evidence-based treatment using medications prescribed for substance use disorder, especially medications that can be prescribed in outpatient settings including buprenorphine and naltrexone. The Surgeon General’s report on facing addiction in America describes substance use disorders as chronic […]
Health Care Cost Institute (HCCI)
The Health Care Cost Institute (HCCI) database contains detailed claims data for approximately 50 million individuals per year (2008-2017) insured with Aetna, Humana, and UnitedHealthcare in all 50 states and the District of Columbia. HCCI includes approximately 30% of all commercially insured individuals in the U.S., as well as claims from Medicare Advantage plans, accounting for approximately 50% of all Medicare Advantage enrollees nationwide. The HCCI data complement MarketScan with the inclusion of Medicare data and a broad mix of employers of various sizes whereas MarketScan contains mostly large employer health plans. The data include claims for all covered services including inpatient, outpatient, physician services, and pharmacy claims.
Bao Y, Wen K, Johnson P, Jeng PJ, Meisel ZF, Schackman BR. Assessing the Impact of State Policies for Prescription Drug Monitoring Programs on High-risk Opioid Prescriptions. Health Affairs. 2018 Oct; 37(10): 1596-1604. PMID: 30273045
Zhang Y, Johnson P, Jeng PJ, Reid MC, Witkin L, Schackman BR, Ancker J, Bao Y. First Opioid Prescription and Subsequent High-Risk Opioid Use: A national study of privately-insured and Medicare Advantage adults. Journal of General Internal Medicine. 2018 Sep; 33(12): 2156-62. PMID: 30206790
A recent study in Health Affairs by CHERISH Research Affiliate Dr. Yuhua Bao and CHERISH investigators Dr. Zachary Meisel and Dr. Bruce Schackman examined the impact of prescription drug monitoring program policies on high-risk opioid prescriptions. Prescription drug monitoring programs (PDMPs) are statewide databases of controlled substances dispensed at retail pharmacies. Currently, all states and […]
The Symphony Health “Integrated Dataverse” contains nationally-representative, detailed, and comprehensive prescription claims data from over 80% of US retail pharmacies that account for approximately 90% of prescriptions filled in the country. Symphony Health data include sales to institutions, including private and government hospitals, clinics, home healthcare providers, HMO captive pharmacies, mail-order pharmacies, and prisons. Data come directly from payers and processors of prescription drug claims, and contain information on consumer out-of-pocket costs, as well as demographic and socioeconomic factors such as age, gender, race, education, income, insurance type, and the prescriber’s 5-digit zip code. All payers are captured by the data, including private, Medicare fee-for-service, managed Medicare, Medicaid, and self-pay.
Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over‐the‐counter status increase pharmacy sales? Health Services Research. 2019. PMID: 30790269
Naloxone is an opioid antagonist rescue medication that reverses the effects of an opioid overdose, and thus a critical tool to prevent fatal opioid overdoses. CHERISH Investigators Drs. Sean Murphy, Jake Morgan, and Bruce Schackman, and CHERISH staff member Philip Jeng, MS predicted pharmacy sales following conversion of naloxone to over-the-counter (OTC) in a new […]